ACE and chronic kidney disease: The FIGARO-DKD trial [30] included more than 7000 persons with T2D and CKD who were receiving maximum tolerated doses of an ACE inhibitor or ARB and had a serum potassium concentration ≤4.8 mmol/L (Figure 3).